Human anti-IL-23 antibodies, compositions, methods and uses
US-9353181-B2 · May 31, 2016 · US
Human anti-IL-23 antibodies, compositions, methods and uses
US9783607B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9783607-B2 |
| Application number | US-201615142765-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 29, 2016 |
| Priority date | Dec 29, 2005 |
| Publication date | Oct 10, 2017 |
| Grant date | Oct 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
First claim
Opening claim text (preview).
What is claimed is: 1. A prefilled syringe containing a liquid pharmaceutical formulation of an isolated IL-23p19 antibody, comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising: a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:50; a CDRL2 amino acid sequence of SEQ ID NO:56; and a CDRL3 amino acid sequence of SEQ ID NO:73, said heavy chain variable region comprising: a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:5; a CDRH2 amino acid sequence of SEQ ID NO:20; and a CDRH3 amino acid sequence of SEQ ID NO:44. 2. The prefilled syringe of claim 1 , wherein the pH of the formulation is 5.8. 3. The prefilled syringe of claim 2 , wherein the liquid pharmaceutical formulation comprises histidine. 4. A prefilled syringe containing a liquid pharmaceutical formulation of an antibody comprising at least one member selected from the group consisting of a light chain variable region having the amino acid sequence of SEQ ID NO:116, a heavy chain variable region having the amino acid sequence of SEQ ID NO:106, and a heavy chain variable region having the amino acid sequence of SEQ ID NO:106 with up to three substitutions from residues 50-66 of the amino acid sequence of SEQ ID NO: 106. 5. The prefilled syringe of claim 4 , wherein the pH of the formulation is 5.8. 6. The prefilled syringe of claim 5 , wherein the liquid pharmaceutical formulation comprises histidine. 7. A prefilled syringe containing a liquid pharmaceutical formulation of an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO:116 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:106. 8. The prefilled syringe of claim 7 , wherein the pH of the formulation is 5.8. 9. The prefilled syringe of claim 7 , wherein the liquid pharmaceutical formulation comprises histidine. 10. A prefilled syringe containing a liquid pharmaceutical formulation of an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO:116, a heavy chain variable region having the amino acid sequence of SEQ ID NO:106, wherein the liquid pharmaceutical formulation comprises histidine and the pH of the formulation is 5.8. 11. The prefilled syringe of claim 2 , wherein the liquid pharmaceutical formulation comprises sucrose. 12. The prefilled syringe of claim 2 , wherein the liquid pharmaceutical formulation comprises poly sorbate 80. 13. The prefilled syringe of claim 2 , wherein the liquid pharmaceutical formulation comprises water. 14. The prefilled syringe of claim 5 , wherein the liquid pharmaceutical formulation comprises sucrose. 15. The prefilled syringe of claim 5 , wherein the liquid pharmaceutical formulation comprises poly sorbate 80. 16. The prefilled syringe of claim 5 , wherein the liquid pharmaceutical formulation comprises water. 17. The prefilled syringe of claim 7 , wherein the liquid pharmaceutical formulation comprises sucrose. 18. The prefilled syringe of claim 7 , wherein the liquid pharmaceutical formulation comprises poly sorbate 80. 19. The prefilled syringe of claim 7 , wherein the liquid pharmaceutical formulation comprises water.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9783607B2 cover?
- A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/244. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).